Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 77-89

  Williams, Kevin P ^a,b   Allensworth, Jennifer L ^b   Ingram, Shalonda M ^a   Smith, Ginger R ^a   Aldrich, Amy J ^b   Sexton, Jonathan Z ^a   Devi, Gayathri R ^b  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lapatinib; QHTS; Redox adaptation; SUM149; SUM190; XIAP

Indexed keywords

ALKYLATING AGENT; ANTIAPOPTOTIC FACTOR; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BLEOMYCIN; BORTEZOMIB; CAPECITABINE; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUDARABINE; GEFITINIB; GW 583340; HYDROXYUREA; LAPATINIB; MANGANESE SUPEROXIDE DISMUTASE; MITHRAMYCIN; MITOMYCIN; MITOXANTRONE; PACLITAXEL; PROTEIN KINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

ADAPTATION; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG APPROVAL; DRUG EFFICACY; DRUG SENSITIZATION; ERBB2 GENE; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; INFLAMMATORY BREAST CANCER; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

LAPATINIB; QHTS; REDOX ADAPTATION; SUM149; SUM190; XIAP;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INFLAMMATORY BREAST NEOPLASMS; QUINAZOLINES; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84880044957     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.017     Document Type: Article

References (60)

1. Brough R., Frankum J.R., Sims D., Mackay A., Mendes-Pereira A.M., Bajrami I., Costa-Cabral S., Rafiq R., Ahmad A.S., Cerone M.A. Functional viability profiles of breast cancer. Cancer Discov. 2011, 1:260-273.
2. Kuo W.L., Das D., Ziyad S., Bhattacharya S., Gibb W.J., Heiser L.M., Sadanandam A., Fontenay G.V., Hu Z., Wang N.J. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 2009, 7:77.
3. Yang R., Niepel M., Mitchison T., Sorger P. Dissecting variability in responses to cancer chemotherapy through systems pharmacology. Clin. Pharmacol. Ther. 2010, 88:34-38.
4. Benes C., Settleman J. Integrating complex genomic datasets and tumour cell sensitivity profiles to address a 'simple' question: which patients should get this drug?. BMC Med. 2009, 7:78.
5. Lee J.K., Havaleshko D.M., Cho H.J., Weinstein J.N., Kaldjian E.P., Karpovich J., Grimshaw A., Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl. Acad. Sci. USA 2007, 104:13086-13091.
6. Sharma S.V., Haber D.A., Settleman J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 2010, 10:241-253.
7. Smith S.C., Baras A.S., Lee J.K., Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Res. 2010, 70:1753-1758.
8. Heiser L.M., Sadanandam A., Kuo W.L., Benz S.C., Goldstein T.C., Ng S., Gibb W.J., Wang N.J., Ziyad S., Tong F. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc. Natl. Acad. Sci. USA 2012, 109:2724-2729.
9. Wolpaw A.J., Shimada K., Skouta R., Welsch M.E., Akavia U.D., Pe'er D., Shaik F., Bulinski J.C., Stockwell B.R. Modulatory profiling identifies mechanisms of small molecule-induced cell death. Proc. Natl. Acad. Sci. USA 2011, 108:E771-780.
10. Dawood S., Cristofanilli M. Inflammatory breast cancer: what progress have we made?. Oncology 2011, 25:264-270.
11. Gonzalez-Angulo A., Hennessy B., Broglio K., Meric-Bernstam F., Cristofanilli M., Giordano S., Buchholz T., Sahin A., Singletary S., Buzdar A. Trends for inflammatory breast cancer: is survival improving?. The Oncologist 2007, 12:904-912.
12. Kleer C.G., Van Golen K.L., Merajver S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res. 2000, 2:423-429.
13. Woodward W.A., Cristofanilli M. Inflammatory breast cancer. Semin. Radiat. Oncol. 2009, 19:256-265.
14. J.M. Goldfarb, J.E. Pippen, Inflammatory breast cancer: the experience of Baylor University Medical Center at Dallas, in: Proceedings (Baylor University. Medical Center), vol. 24, 2011, pp. 86-88.
15. Dawood S., Broglio K., Buzdar A.U., Hortobagyi G.N., Giordano S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J. Clin. Oncol. 2010, 28:92-98.
16. Robertson F.M., Bondy M., Yang W., Yamauchi H., Wiggins S., Kamrudin S., Krishnamurthy S., Le-Petross H., Bidaut L., Player A.N., Barsky S.H., Woodward W.A., Buchholz T., Lucci A., Ueno N., Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA. Cancer J. Clin. 2010, 60:351-375.
17. Johnston S., Trudeau M., Kaufman B., Boussen H., Blackwell K., LoRusso P., Lombardi D.P., Ben Ahmed S., Citrin D.L., DeSilvio M.L. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J. Clin. Oncol. 2008, 26:1066-1072.
18. Burris H.A., Hurwitz H.I., Dees E.C., Dowlati A., Blackwell K.L., O'Neil B., Marcom P.K., Ellis M.J., Overmoyer B., Jones S.F. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005, 23:5305-5313.
19. Chen F.L., Xia W., Spector N.L. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin. Cancer Res. 2008, 14:6730-6734.
20. Li J., Gonzalez-Angulo A.M., Allen P.K., Tse K.Y., Woodward W.A., Ueno N.T., Lucci A., Krishnamurthy S., Gong Y., Bondy M.L. Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. The Oncologist 2011, 16:1675-1683.
21. Petrelli F., Cabiddu M., Ghilardi M., Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?. Expert Opin. Invest. Drugs 2009, 18:1467-1477.
22. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Discov. 2009, 8:579-591.
23. Allensworth J.L., Aird K.M., Aldrich A.J., Batinic-Haberle I., Devi G.R. XIAP inhibition and generation of reactive oxygen species enhances TRAIL sensitivity in inflammatory breast cancer cells. Mol. Cancer Ther. 2012, 11:1518-1527.
24. Aird K.M., Ding X., Baras A., Wei J., Morse M.A., Clay T., Lyerly H.K., Devi G.R. Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol. Cancer Ther. 2008, 7:38-47.
25. Aird K.M., Ghanayem R.B., Peplinski S., Lyerly H.K., Devi G.R. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. Mol. Cancer Ther. 2010, 9:1431-1442.
26. Aird K.M., Allensworth J.L., Batinic-Haberle I., Lyerly H.K., Dewhirst M.W., Devi G.R. ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res. Treat. 2012, 132:109-119.
27. Forozan F., Veldman R., Ammerman C.A., Parsa N.Z., Kallioniemi A., Kallioniemi O.-P., Ethier S.P. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br. J. Cancer 1999, 81:1328-1334.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65:55-63.
29. Amantana A., London C.A., Iversen P.L., Devi G.R. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol. Cancer Ther. 2004, 3:699-707.
30. Abraham V.C., Towne D.L., Waring J.F., Warrior U., Burns D.J. Application of a high-content multiparameter cytotoxicity assay to prioritize compounds based on toxicity potential in humans. J. Biomol. Screen. 2008, 13:527-537.
31. Carpenter A.E., Jones T.R., Lamprecht M.R., Clarke C., Kang I.H., Friman O., Guertin D.A., Chang J.H., Lindquist R.A., Moffat J., Golland P., Sabatini D.M. Cell profiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol. 2006, 7:R100.
32. Zhang J., Chung T., Oldenburg K. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4:67-73.
33. Rangwala F., Williams K.P., Smith G.R., Allensworth J., Thomas Z., Lyerly H.K., Diehl A.M., Morse M.A., Devi G.R. Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 2012, 12:402.
34. Thomas Z., Gibson W., Sexton J., Aird K., Ingram S., Aldrich A., Lyerly H., Devi G., Williams K. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration. Br. J. Cancer 2011, 104:1575-1586.
35. Brunton L.L., Lazo J.S., Parker K.L. Goodman & Gilman's the Pharmacological Basis of Therapeutics 2006, McGraw-Hill, New York.
36. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68:8643-8653.
37. Gheeya J.S., Chen Q.R., Benjamin C.D., Cheuk A.T., Tsang P., Chung J.Y., Metaferia B.B., Badgett T.C., Johansson P., Wei J.S. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol. Ther. 2009, 8:2386-2395.
38. Labay E., Efimova E., Quarshie B., Golden D., Weichselbaum R., Kron S. Ionizing radiation-induced foci persistence screen to discover enhancers of accelerated senescence. Int. J. High Throughput Screen. 2011, 2:1-13.
39. Ulukaya E., Colakogullari M., Wood E.J. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy 2004, 50:43-50.
40. Riss T.L., Moravec R.A., Niles A.L. assay development for cell viability and apoptosis for high-throughput screening. A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery 2009, 99-122. CRC Press. T. Chen (Ed.).
41. Sexton J., Williams K. Evaluating the peroxisomal phenotype in high-content toxicity profiling. High-Throughput Screening Methods in Toxicity Testing 2013, 501-518. Wiley, New Jersey. P. Steinberg (Ed.).
42. Valiathan C., McFaline J.L., Samson L.D. A rapid survival assay to measure drug-induced cytotoxicity and cell cycle effects. DNA Repair 2011, 11:92-98.
43. Malo N., Hanley J.A., Cerquozzi S., Pelletier J., Nadon R. Statistical practice in high-throughput screening data analysis. Nat. Biotechnol. 2006, 24:167-175.
44. Dong H.M., Liu G., Hou Y.F., Wu J., Lu J.S., Luo J.M., Shen Z.Z., Shao Z.M. Dominant-negative E-cadherin inhibits the invasiveness of inflammatory breast cancer cells in vitro. J. Cancer Res. Clin. Oncol. 2007, 133:83-92.
45. Hoffmeyer M.R., Wall K.M., Dharmawardhane S.F. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer Cell Int. 2005, 5:11.
46. Ignatoski K., Ethier S. Constitutive activation of pp 125fak in newly isolated human breast cancer cell lines. Breast Cancer Res. Treat. 1999, 54:173-182.
47. Singh B., Irving L., Tai K., Lucci A. Overexpression of COX-2 in Celecoxib-resistant breast cancer cell lines. J. Surg. Res. 2010, 163:235-243.
48. Wu M., Wu Z., Rosenthal D., Rhee E., Merajver S. Characterization of the roles of RHOC and RHOA GTPases in invasion, motility, and matrix adhesion in inflammatory and aggressive breast cancers. Cancer 2010, 116:2768-2782.
49. Robertson F.M., Chu K., Fernandez S.V., Mu Z., Zhang X., Liu H., Boley K.M., Alpaugh R.K., Ye Z., Wright M.C., Luo A.Z., Oraes R., Wu H., Zook M., Barsky S.H., Krishnamurthy S., Cristofanilli M. Genomic profiling of pre-clinical models of inflammatory breast cancer identifies a signature of epithelial plasticity and suppression of TGFß signaling. J. Clin. Exp. Path. 2012, 2:119.
50. Foster F.M., Owens T.W., Tanianis-Hughes J., Clarke R.B., Brennan K., Bundred N.J., Streuli C.H. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 2009, 11:R41.
51. Li Y., Jian Z., Xia K., Li X., Lv X., Pei H., Chen Z., Li J. XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics. Pancreas 2006, 32:288-296.
52. Shrikhande S.V., Kleeff J., Kayed H., Keleg S., Reiser C., Giese T., Buchler M.W., Esposito I., Friess H. Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res. 2006, 26:3265-3273.
53. He X., Khurana A., Maguire J.L., Chien J., Shridhar V. HtrA1 sensitizes ovarian cancer cells to cisplatin-induced cytotoxicity by targeting XIAP for degradation. Int. J. Cancer 2011, 130:1029-1035.
54. Tong Q.-S., Zheng L.-D., Wang L., Zeng F.-Q., Chen F.-M., Dong J.-H., Lu G.-C. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther. 2005, 12:509-514.
55. Sapi E., Alvero A.B., Chen W., O'Malley D., Hao X.-Y., Dwipoyono B., Garg M., Kamsteeg M., Rutherford T., Mor G. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol. Res. 2004, 14:11-12.
56. Cardaci S., Filomeni G., Ciriolo M.R. Redox implications of AMPK-mediated signal transduction beyond energetic clues. J. Cell Sci. 2012, 125:2115-2125.
57. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
58. Charafe-Jauffret E., Ginestier C., Iovino F., Tarpin C., Diebel M., Esterni B., Houvenaeghel G., Extra J.-M., Bertucci F., Jacquemier J. Aldehyde dehydrogenase 1-Positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin. Cancer Res. 2010, 16:45-55.
59. Debeb B.G., Cohen E.N., Boley K., Freiter E.M., Li L., Robertson F.M., Reuben J.M., Cristofanilli M., Buchholz T.A., Woodward W.A. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res. Treat. 2012, 134:495-510.
60. Rosenthal D.T., Zhang J., Bao L., Zhu L., Wu Z., Toy K., Kleer C.G., Merajver S.D. RhoC impacts the metastatic potential and abundance of breast cancer stem cells. PLoS One 2012, 7:e40979.